Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Everolimus-based therapy versus conventional therapy for refractory breast cancer patients with PI3K/AKT/mTOR mutations

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Zhanhong Chen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

Z. Chen1, Y. Zheng1, W. Cao1, Y. Zhang2, S. Cai2, X. Shao1, J. Huang1, W. Ye1, Y. Huang1, Y. Yin3, X. Wang1

Author affiliations

  • 1 Department Of Breast Medical Oncology, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 2 The Medical Department, 3D medicines Inc., 201114 - Shanghai/CN
  • 3 Department Of Oncology, Jiangsu Province Hospital, 210029 - nanjing/CN
More

Resources

Background

Molecular screening using next generation sequencing (NGS) with the aim of guiding therapy for patients with refractory cancer, is becoming increasingly more common in clinical practice. Given that tumors with alterations in PI3K/ATK/mTOR (PI3K) pathway exhibit sensitivity to mTOC1 inhibitor everolimus, everolimus is often off-label used to target PI3K pathway. However, efficacy of off-label-use of everolimus in refractory breast cancer is unknown. We conducted this retrospective study to assess the efficacy of molecular matched off-label use of everolimus for refractory breast cancer patients with mutations in PI3K pathway, compared with conventional therapy.

Methods

Patients with refractory metastatic breast cancer who received NGS with the aim of guiding therapy between 2015 and 2017, were screened for eligibility at two sites in China. Patients with mutations in PI3K pathway and treated with everolimus-based or conventional therapy were included. Everolimus was used outside its indications. The primary outcome was progression-free survival (PFS). Secondary outcomes were overall response rate (ORR), disease control rate (DCR) and safety profile.

Results

33 patients with mutations in PI3K pathway were included in this analysis. 18 (54.5%) patients were hormone receptor positive and 14 (42.4%) patients were HER2 positive. 20 patients received everolimus-based therapy and 13 patients received conventional therapy. The PFS was shorter in everolimus group than conventional group (median, 2.05 vs 6.1 months; HR, 4.45; 95% CI, 1.64-12.10; P = 0.0016). ORR was 14.3% (2/14) in everolimus group and 23.1% (3/13) in conventional group (P = 0.648). DCR was 35.7% (5/14) in everolimus group and 100% (13/13) in conventional group (P = 0.001). The incidence of grade 3 or worse treatment-related adverse event was similar between groups (5 [38.5%] of 13 in everolimus group, 5 [25.0%] of 20 in conventional group, P = 0.393).

Conclusions

The off-label use of everolimus to target the PI3K/AKT/mTOR pathway is associated with poorer outcome in patients with refractory breast cancer. These data suggests that off-label use of everolimus to target PI3K/AKT/mTOR should not be encouraged.

Clinical trial identification

Legal entity responsible for the study

Yongmei Yin, Xiaojia Wang.

Funding

National Natural Science Foundation of China.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Working arrangements after cancer diagnosis: who, what, when and how?

Presenter: Caroline Alleaume

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)

Presenter: Sebastian Bauer

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings